Nonviable cell preparations of Burkholderia mallei, the causative agent of glanders, were evaluated as potential vaccine candidates in a BALB/c murine model. Three different B. mallei cell preparations plus Alhydrogel were evaluated: a heat-killed preparation, an irradiation-inactivated preparation, and a preparation of a capsule-negative mutant strain which had been irradiation inactivated. BALB/c mice were vaccinated twice with the different B. mallei preparations, and spleens and sera were collected to determine their cellular and humoral immune responses. All three bacterial cell preparations had essentially the same results in two cellular immune response assays. In a splenocyte proliferation assay, the amount of cell proliferation in response to the homologous immunogen, concanavalin A, or lipopolysaccharide was similar for all the cell preparations. Also, splenocytes from the inoculated mice expressed interleukin 2 (IL-2), gamma interferon, and small amounts of IL-4 and IL-5, and more IL-10 cytokine in the presence of the homologous antigen. When the immunoglobulin subclasses from these mice were examined, they all produced higher levels of IgG1 than IgG2a subclasses. The higher ratio of IgG1 to IgG2a was not due to the amount of the immunogen or the adjuvant (Alhydrogel) used in the BALB/c mice. The cell preparations did not protect the vaccinated mice from a live challenge (>300 50% lethal doses). Our results suggest that in BALB/c mice, a mixed T-helper-cell-like response to nonviable B. mallei is obtained, as demonstrated by a Th1-and Th2-like cytokine response and a Th2-like subclass immunoglobulin response. This may be the reason for the inability of the B. mallei cells that were examined as candidate vaccines to protect the mice from a live challenge.
Glanders is primarily an infection of solipeds (horses, mules, and donkeys) and is caused by Burkholderia mallei, a gramnegative, nonmotile, oxidase-positive bacillus (7, 19) . Studies by Loeffler and Schuetz in 1882 were the first to identify B. mallei as the etiologic agent of glanders (2) . The glanders organism was recently classified as Pseudomonas mallei, but then it was reclassified with the closely related species Burkholderia pseudomallei and Burkholderia thailandensis based on their 16S rRNA homology (3, 20) . Glanders in the past was prevalent worldwide because of the wide use of solipeds, but as the result of a general decrease in their use for transportation and as work animals, and stringent health enforcement procedures, the incidence has decreased. Glanders is now found primarily in Asia, Africa, and the Middle East. Infection of solipeds by B. mallei may be presented in two general forms: (i) a chronic form found primarily in horses and (ii) an acute form found primarily in donkeys and mules. The chronic form of the disease may be presented separately or simultaneously as a pulmonary disease, an upper respiratory disease, or a cutaneous disease (farcy). Symptoms for the acute form of the disease include the presence of high temperature, depression, shortness of breath, diarrhea, and rapid weight loss (1) . Death may occur after a few weeks with an acute infection, whereas the chronic form of glanders may last for years and may end in death. The disease is transmitted through close contact with diseased solipeds or by soliped products through the skin or nasal or mucosal passages. B. mallei infection in humans may also be either a chronic or acute disease.
In the United States, the last two reported cases of B. mallei infection were the result of laboratory exposure to the microorganism (5, 12) . From these two reports, it appears that the routes of infection were either inhalation of an aerosolized cell suspension or direct contact with the microorganism. In the earlier report, sulfadiazine administered intravenously was the treatment of choice (12) , while in the later report, rapid improvement of the patient occurred after treatment with imipenem and doxycycline (5) . Currently, there is no animal or human vaccine against infection with B. mallei. Because of its highly infectious and debilitating nature, B. mallei is considered to be a potential biological weapon (4) . With this prospect as a possibility, we are interested in developing a vaccine for B. mallei infection. In this study, we report the results of our initial experiments on the cellular and humoral immune response to nonviable B. mallei cells in BALB/c mice.
MATERIALS AND METHODS
Bacterial strains, growth conditions, and antigen preparation. B. mallei ATCC 23344 (hereafter in this work identified as GB15.1-2) was serially passaged three times through Syrian hamsters (spleen suspensions) and then stored as a glycerol stock (50% glycerol in 1ϫ phosphate-buffered saline [PBS] [1.7 mM KH 2 PO 4 ; 5 mM Na 2 HPO 4 ; 150 mM NaCl, pH 7.4]) at Ϫ70°C. For antigen preparation, a suspension of the glycerol stock was inoculated into 4% glycerol-1% tryptone (Difco, Becton Dickinson, Sparks, Md.) broth (GTB) and grown overnight at 37°C with shaking (250 rpm). After 20 to 24 h of growth, the cells were pelleted by centrifugation and suspended in sterile Hanks' balanced salt solution. The pellet was appropriately diluted to the desired optical density (OD) at 660 nm. Cell concentration was determined by comparison with a standard curve (weight [in milligrams per milliliter] versus OD at 660 nm). Heat-killed cells (HKGB15) were prepared by heating the cells at 65°C for 30 min. Irradi-ation-inactivated cells (IRGB15) were prepared by exposure to 2.1 megarads of gamma radiation. A capsule-negative mutant of B. mallei GB15.1-2 (CapGB15) was created by DeShazer et al. (designated as "DD3008" in their report [9] ), and cells were prepared and irradiation inactivated by gamma radiation (2.1 megarads). Sterility of all inactivated cell preparations was verified by plating on 4% glycerol-1% tryptone (Difco)-1.5% agar (Difco) plates.
Mice, vaccinations, and challenges. Female, 6-to 8-week-old, BALB/c mice obtained from the National Cancer Institute (Frederick, Md.) were used in all studies. Mice, four to five per group, were vaccinated subcutaneously with 100 g (unless stated differently) of nonviable B. mallei cell preparation mixed with 100 g of Alhydrogel (Superfos Biosector G/S, Vedbaek, Denmark) in a total volume of 0.2 ml. Unless stated differently, mice were inoculated twice, 21 days apart. Three weeks after the second boost, mice were anesthetized for serum collection and killed by cervical dislocation, and their spleens were removed and cultured as described below. In challenge studies, mice were injected intraperitoneally (i.p.) with 0. Spleen cell cultures. Spleen cell cultures were prepared from vaccinated mice 21 days after the second vaccination, essentially as described by Jankovic et al. (13) . Individual spleens or two spleens from each group were combined per sample, and cell suspensions were prepared after lysis of the erythrocytes (red blood cell lysing buffer; Sigma, St. Louis, Mo.) and adjusted to 2 ϫ 10 6 to 10 ϫ 10 6 cells/ml in RPMI medium (BioWhittaker, Walkersville, Md.) containing 10% fetal calf serum (HyClone, Logan, Utah, or BioWhittaker), 25 mM HEPES, 2 mM glutamine, 1 mM sodium pyruvate, nonessential amino acids, 50 M 2-mercaptoethanol, penicillin (100 U/ml), and streptomycin (100 g/ml).
Proliferation assay. To evaluate the extent of spleen cell proliferation in the presence of specific antigens, 2 ϫ 10 6 splenocytes/ml from vaccinated mice were incubated in Costar (no. 3596) 96-well, flat-bottom dishes (Corning Inc., Corning, N.Y.) in a final volume of 200 l of RPMI culture medium. The antigens and mitogens were prepared in RPMI culture medium and used at the indicated final concentration: HKGB15, IRGB15, or CapGB15, 10 g/ml; concanavalin A (ConA) (Sigma), 5 g/ml; Salmonella enterica serovar Typhimurium lipopolysaccharide (LPS) (Sigma), 1 g/ml. Cytokine assays. Expression of cytokines was measured in the supernatants of stimulated spleen cell cultures prepared from vaccinated mice. Spleen cells prepared as described above were grown in Costar (no. 3524) 24-well culture dishes (Corning Inc.) at a concentration of 5 ϫ 10 6 /ml in a final volume of 1.0 ml. The same stimulatory antigens (HKGB15, IRGB15, CapIRGB15, ConA, and LPS) were used at the same concentrations (per milliliter) as used in the proliferation assays, and cell cultures in duplicate were incubated at 37°C with 5% CO 2 for 20 to 72 h. In initial studies, we detected the expression of interleukin 2 (IL-2), IL-10, IL-12, and gamma interferon (IFN-␥) after 20 h of incubation. There was some increase in the amount of these cytokines after 48 h but also an increase in the background. Because of this we are reporting the amount of these cytokines expressed after approximately 20 h. Little IL-4 and IL-5 were expressed under the same conditions after 20 to 72 h of incubation. For these later cytokines we are reporting the amount expressed after 20 or 48 h of incubation. We determined the amount of cytokine expressed by a cytokine capture, enzymelinked immunosorbent assay (ELISA) (OptEIA ELISA Sets) performed as recommended by the manufacturer (BD Pharmingen, San Diego, Calif.) with Immulon 2 HB, 96-well, round-bottom plates (Dynex Technologies, Chantilly, Va.). The plates were read at 450 nm with 570 nm as a reference wavelength. Samples were run in triplicate, compared to a standard curve, and results were reported as the mean concentration (in picograms per milliliter) Ϯ 1 SD. The sensitivity of the cytokine ELISAs was approximately 7.5 to 15 pg/ml. Antibody assays. Immunoglobulin (Ig) class (IgG, IgM, and IgA) and subclass (IgG1, IgG2a, IgG2b, and IgG3) titers in vaccinated mice were determined by an ELISA performed in 96-well, Immulon 2 HB, round-bottom plates (Dynex Technologies). B. mallei cells (HKGB15, IRGB15, or CapIRGB15), used as antigens, were diluted in 0.1 M carbonate buffer, pH 9.5, to a concentration of 10 g/ml, and 50 l of diluted cells was placed into wells. Plates were stored overnight at 4°C. The plates were washed with washing solution (1ϫ PBS, 0.05% Tween 20), and incubated with 100 l of blocking solution (1ϫ PBS, 1% bovine serum albumin, 0.05% Tween 20) for 1 h at 37°C. Twofold dilutions of mouse sera were made with blocking solution in triplicate, and plates were incubated for 1 h at 37°C. After the plates were washed, 50 l of 1/5,000-diluted anti-Ighorseradish peroxidase conjugate (anti-Ig class or subclass conjugate) obtained from Southern Biotechnology Associates, Inc. (Birmingham, Ala.) was added to each well, and plates were incubated for 1 h at 37°C. After the plates were washed, 50 l of a buffered hydrogen peroxide and 3,3Ј,5,5Ј-tetramethylbenzidine solution (BD Pharmingen) was added to each well, and plates were incubated for 15 min at room temperature. The reaction was stopped with 25 l of 2 N sulfuric acid, and the amount of bound antibody was determined colorimetrically by reading at 450 nm with a reference filter (570 nm). The results are reported as the reciprocal of the highest dilution giving a mean OD of at least 0.1 (which was at least twice the background) Ϯ 1 SD. The titer of antibody (anti-Ig class or subclass) in mice vaccinated with the adjuvant only was usually less than or equal to 50.
Statistics. All assays were performed in triplicate, and results were reported as the mean Ϯ SD. Statistics were determined by using InStat version 3.0, which uses the Mann-Whitney, nonparametric method for comparing two unpaired groups, and two-tailed P values were reported. In the challenge studies, comparisons between tests were done by the Fisher exact test using SAS version 8.0, with statistical significance considered to be indicated by a P value of Ͻ0.05. (Table 1) . At the same time, we saw a 1.5-to 1.6-fold increase (P Ͻ 0.01) in the incorporation of label with the homologous antigen from splenocytes from vaccinated mice over splenocytes obtained from mice that received adjuvant only. As stimulating-antigen controls, we used ConA and LPS and obtained an increase of more than 188-and 56-fold, respectively, in the amount of [ 3 H]TdR incorporated over that observed in cells incubated with medium only, although these results were either the same or 1.2-fold greater than that obtained with the control cells. Thus, there was specific stimulation of the splenocytes with the homologous antigen, and the extent of proliferation of the immune cells from the three different groups of B. mallei-vaccinated mice did not differ appreciably.
RESULTS

Proliferation of stimulated spleen cells obtained from
Th1-like and Th2-like expression of cytokines by stimulated spleen cells from B. mallei-vaccinated mice. To determine the type of cytokines expressed from the spleen cells obtained from the vaccinated mice when incubated in the presence of the homologous immunogen, HKGB15, IRGB15, and CapGB15, cells were used to restimulate splenocyte cell cultures for 20 to 72 h. We found that the expression of IL-2 and IFN-␥ could be detected at the earliest time points (18 to 20 h) in the presence of the three B. mallei cell antigens (P Ͻ 0.01), but little IL-12 could be detected (Table 2) . At the same, we found large amounts of IL-2 and smaller amounts of IFN-␥ expressed by splenocytes in the presence of ConA, except in both cases it was the same or just a little more than that expressed in the control cells. LPS stimulated the expression of large amounts of IFN-␥, but not IL-2 or IL-12; however, the amount of IFN-␥ expressed was essentially similar to that amount expressed by control splenocytes.
We then examined the expression of IL-4, IL-5, and IL-10 by these spleen cells when incubated in the presence of the three different B. mallei cell preparations (Table 3) (Table 3) was upregulated, even at the earliest time points (20 h ). There was a slight-to-moderate increase in expression of IL-10 by these same splenocytes in the presence of ConA or LPS compared to the control cells. In summary, it appeared that both Th1-like cytokines (IL-2 and IFN-␥) and Th2-like cytokines (IL-4, IL-5, and IL-10) were expressed in the presence of the B. mallei cell preparations.
Ig class and subclass response to nonviable B. mallei. In addition to examining the cellular immune response to B. mallei, we wanted to examine the Ig class and Ig subclass response to the glanders organism. The HKGB15-, IRGB15-, and CapGB15-vaccinated mice gave a good IgG response (titers of 280,000, 1,000,000, and 300,000, respectively). The IgM response was approximately the same (titer of 10,000) against all the nonviable B. mallei cell preparations. The IgA immune response to the same B. mallei cells was generally not measurable (titer Ͻ 50), as was the case with the Ig immune response to the adjuvant-only control group (titer Ͻ 50).
In addition to examining the class of antibodies produced in BALB/c mice in response to the B. mallei cell preparations, we evaluated the IgG1 and IgG2a subclass response to B. mallei in the presence and absence of the adjuvant (Alhydrogel). Of the two Ig subclasses we examined which were produced in the presence of the adjuvant, IgG1 was the predominant Ig subclass induced by the three different B. mallei cell preparations, as shown in Table 4 . We consistently found this result in studies on the immune response to B. mallei cells in BALB/c mice. We did not always see as much of a difference between the levels of IgG1 in response to IRGB15 or HKGB15 cells. The level of Ig subclasses in mice vaccinated with the adjuvant only was typically less than 50 (data not shown), which we considered to be a negative response.
In the absence of the adjuvant there was still a good IgG1 and IgG2a subclass response to the IRGB15 and CapGB15 cells, even though one-half as many cells were used for the vaccination (Table 4 , experiment II). In the case with the HKGB15 cells, the Ig subclass-specific titer decreased between 13-and 15-fold under the same conditions. Nevertheless, the IgG1 subclass-specific titer was still greater than the IgG2a subclass-specific titer in the absence of the adjuvant for the B. mallei cell preparations, and the adjuvant did not affect the ratio of IgG2a to IgG1.
In addition to evaluating the effect of the adjuvant on the immune response to B. mallei, we examined the effect of the amount of immunogen on the IgG1 and IgG2a subclass response in BALB/c mice. Mice were vaccinated twice with B. mallei IRGB15 cells (with adjuvant), ranging from 25 to 100 g, or B. mallei CapGB15 cells (with adjuvant), ranging from 10 to 100 g. Table 5 shows that the ratio of IgG2a to IgG1 did not change appreciably with different amounts of B. mallei IRGB15 cells (0.04 to 0.1) or B. mallei CapGB15 cells (0.05 to 0.62), although at the same time the titers of these two Ig subclasses generally decreased with dosage. In summary, the predominate Ig subclass antibody response to nonviable B. mallei cells was IgG1, and as a result the ratio of IgG2a to IgG1 was consistently less than 1.0. These results suggest that a Th2-like Ig subclass antibody response was induced by nonviable B. mallei cells in BALB/c mice independent of the adjuvant or dosage used in these studies.
Challenge of B. mallei-vaccinated BALB/c mice. We next challenged B. mallei-vaccinated mice to determine if there was any protective efficacy in the B. mallei cell preparations. Table  6 shows the results of this study. In the first part of the study (Table 6 , group I), HKGB15, IRGB15, and CapGB15 B. mallei cells were each used to vaccinate mice and as boosters (five mice per cell type). Four weeks after the second injection, the vaccinated mice were challenged i.p. with 2.3 ϫ 10 8 B. mallei (GB15.1-2) cells (329 50% lethal doses [LD 50 s]). The LD 50 of B. mallei GB15.1-2 is 7 ϫ 10 5 CFU/ml for 6-to 8-week-old BALB/c mice (10) . As shown in Table 6 , group I, in the three sets of vaccinated mice challenged with approximately 329 LD 50 s, all but one of the mice did not survive the challenge. The spleen of the surviving mouse was greatly oversized and heavily infected with B. mallei cells.
In the second group of mice shown in Table 6 , group II, we wanted to demonstrate that although the B. mallei CapGB15 mutant was similar to the wild-type B. mallei strain in its inability to provide any protective efficacy as shown above, the outcome of challenging nonviable B. mallei-vaccinated BALB/c mice with the B. mallei CapGB15 mutant versus the B. mallei GB15.1-2 cells was much different. Three sets of mice were vaccinated twice with B. mallei IRGB15, and a fourth set of mice received only the adjuvant. One group of vaccinated mice and the group of mice receiving only the adjuvant were challenged with 2.8 ϫ 10 8 B. mallei GB15.1-2 cells (approximately 400 LD 50 s). In the first group of mice, there was one surviving mouse 3 weeks after challenge, while in the second group of mice (adjuvant only), there were no survivors after challenge. Like the one surviving mouse from the first group of mice described above, the lone surviving mouse had a greatly oversized and heavily infected spleen (approximately 6 ϫ 10 7 CFU/ml). As for the two remaining groups of B. mallei IRGB15-vaccinated mice in this study, one was challenged with 2.8 ϫ 6 cells by aerosol challenge (9) . All but one mouse survived the challenge with the B. mallei CapGB15 cells at the lower and higher cell counts. Unlike the surviving mouse from the wild-type B. mallei GB15.1-2 challenge, the spleens of the surviving mice challenged with the B. mallei CapGB15 mutant cell appeared more normal, and they did not harbor any live B. mallei cells. The results of these challenge studies demonstrate that nonviable B. mallei cell preparations used in our studies were unable to protect vaccinated mice from a live challenge of B. mallei GB15.1-2 cells.
Challenge of vaccinated mice with less than a lethal dose of B. mallei. During the course of our studies, we challenged a group of HKGB15-, IRGB15-, and CapGB15-vaccinated mice with approximately 2.4 ϫ 10 7 CFU or 34 LD 50 s of B. mallei GB15.1-2 cells (Table 7) . Unlike in the previous challenge studies described above, most of the challenged mice survived. We measured the Ig class-and subclass-specific antibody levels in the surviving mice. We saw a good IgG and IgM response in all the surviving, vaccinated mice except those inoculated with the adjuvant only. The mice that had been vaccinated with the B. mallei CapGB15 mutant produced twice as much of both IgG and IgM classes of antibodies as the mice vaccinated with either B. mallei HKGB15 or IRGB15 cells. The Ig2a-to-IgG1 ratio for these mice ranged from 0.25 to 1.0, with the highest ratio belonging to the B. mallei IRGB15-inoculated mice and the lowest belonging to the B. mallei CapGB15-inoculated mice. It is noteworthy that there were two surviving mice in the group of challenged mice inoculated with the adjuvant only. The difference between the number of mice surviving in the B. mallei (IRGB15)-vaccinated group (five of five) and the number of mice surviving in the adjuvant-only group (two of five) a Two immunizations were given 3 weeks apart, and sera were obtained 3 weeks after the last booster.
b The isotype titer is the mean of those obtained from four mice per group Ϯ SD. The titer of mice treated with adjuvant only in both cases was less than 50 as determined with IRGB15 cells. was not significant (P ϭ 0.17). In the adjuvant-only mice, the IgG and IgM cell-specific antibody levels were the same (Table  7 , adjuvant), although they were much lower than those in the vaccinated mice. However, when the IgG1 and IgG2a (IRGB15-specific) subclasses were determined, the IgG2a-toIgG1 ratio was 4.0. This ratio was higher than that observed for the surviving mice in the B. mallei-vaccinated group. As in the previous study with a higher challenge dose, the spleens in the surviving mice given the lower challenge dose in both the B. mallei GB15.1-2-vaccinated mice and control mice were greatly enlarged and heavily infected with B. mallei. Although the outcome of this study with respect to the number of mice surviving challenge was different from that in the previous section with the higher-LD 50 dose challenge with B. mallei GB15.1-2 cells, the spleens in the surviving mice in both studies were similarly enlarged and infected.
DISCUSSION
The results of our studies suggest that nonviable B. mallei cells may not be a desirable vaccine candidate, at least in the present unattenuated form. We obtained a mixed Th1-and Th2-like cytokine response and a Th2-like Ig subclass response to the B. mallei cell preparations (14, 15) . IRGB15 cells induced the highest level of IgG, followed by the CapGB15 mutant cells and then the HKGB15 cells. More revealing, however, was the Ig subclass response to B. mallei cells. In all cases, IgG1 was the predominate subclass response to the B. mallei cells, even in the absence of the Alhydrogel adjuvant used in our studies. Although aluminum hydroxide adjuvants are considered Th2-like stimulating adjuvants (6, 11) , in our case a Th2-like Ig subclass response was seen even without the adjuvant.
The inability of the nonviable B. mallei cells to protect BALB/c mice from a parenteral challenge may be in part another characteristic like the mixed cytokine response to an inadequate candidate vaccine. Two different cell challenge concentrations were used in one of our studies: low, at 2.4 ϫ 10 7 CFU (34 LD 50 s), and high, at 2.3 ϫ 10 8 to 2.8 ϫ 10 8 CFU (329 to 400 LD 50 s). In the study with the higher cell challenge, the B. mallei-vaccinated mice did not survive the B. mallei GB15.1-2 challenge. Only one mouse from the B. mallei IRGB15-vaccinated group survived. However, for the challenge at the lower concentration, all the mice except one survived the challenge. These results were unexpected because the LD 50 for B. mallei in BALB/c mice was reported to be 7 ϫ 10 5 CFU (10). This was very close to the results of a previous study with BALB/c mice, which reported the LD 50 for a parenteral challenge to be approximately 4.2 ϫ 10 5 CFU (16). The results of our challenge study might be explained by at least two factors. First, the mice used in this study were much older and larger when they were challenged: approximately 6 to 8 weeks old in the initial study (10) versus 17 weeks old in this study. The older mice may have been able to tolerate the challenge dose better than the younger mice because of a more-developed immune system (18) . Second, the LD 50 of the lower-dose challenge in our study was only 34-fold higher than the reported LD 50 , which may be below or close to the LD 50 for 17-week-old BALB/c mice challenged with B. mallei. On the other hand, the difference between the reported LD 50 and our higher-dose challenge study was approximately 329-fold. These two factors, age and challenge dose, may account for the number of survivors in the low-dose challenge group and the number of survivors in the adjuvant control group. Nevertheless, it was interesting to see a difference between the number of survivors in the low-dose challenge group and the adjuvant control group of mice. Whether the B. mallei cell preparations had some efficacy in this study was not clear because of the small number of animals used. Furthermore, the spleens of all survivors from all groups in this study were still heavily infected with B. mallei cells. The fourfold increase in the IgG2a/IgG1 ratio between the B. mallei IRGB15-vaccinated mice and the mice inoculated with adjuvant only may not have been enough to completely protect the control mice.
Although the murine immune response appeared to be much the same for the wild type (capsulated) and the uncapsulated mutant of B. mallei, we saw a much different result in our challenge studies with these two strains. We confirmed the observation reported by DeShazer et al. (9) , i.e., that the capsular polysaccharide of B. mallei was a major virulence factor. The capsule component is closely related to that of B. pseudomallei (17) , the cause of melioidosis in human and animals. In this study, it was shown that the LPS and capsule structure of B. pseudomallei are responsible for both resistance and virulence of the microorganism (8, 17) . DeShazer et al. (9) showed in two different animal models of B. mallei infection (Syrian hamsters and BALB/c mice) that the capsule-negative mutant was attenuated. They also suggested from the results of a failed rechallenge experiment that the capsule-negative mutant may not be a good vaccine candidate. Our studies found that two vaccinations with the irradiation-inactivated, capsulenegative strain of B. mallei does not provide any protection b Mice were observed for 21 days after the challenge. c Sera were collected from the survivors and pooled, and titers were determined in triplicate and reported as means Ϯ SDs. The titer for the group treated with adjuvant only was determined with IRGB15 cells.
from a challenge with a wild-type strain of B. mallei. Whether the capsular polysaccharide can be a protective immunogen in another context, such as when it is coupled to a protein carrier, remains to be demonstrated. We are continuing our studies on the development of candidate vaccines for B. mallei infections. Whether a modified whole-cell or subunit vaccine will eventually prove to be efficacious awaits further investigation.
